Clinical trial designs incorporating predictive biomarkers
- 1 February 2016
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 43, 74-82
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Adaptive Clinical Trials: The Promise and the CautionJournal of Clinical Oncology, 2011
- Outcome-Adaptive Randomization: Is It Useful?Journal of Clinical Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Randomized Clinical Trials With Biomarkers: Design IssuesJNCI: Journal of the National Cancer Institute, 2010
- Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit AllJournal of Biopharmaceutical Statistics, 2009
- Using short‐term response information to facilitate adaptive randomization for survival clinical trialsStatistics in Medicine, 2009
- Randomized Phase III Clinical Trial Designs for Targeted AgentsClinical Cancer Research, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008